Germany · Delayed Price · Currency is EUR Autolus Therapeutics Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 650 |
| CEO | Christian Itin |
Contact Details
Address: The Mediaworks London, W12 7FP United Kingdom | |
| Phone | 44 20 3829 6230 |
| Website | autolus.com |
Stock Details
| Ticker Symbol | 6A3A |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christian Itin | Chief Executive Officer |
| Robert Dolski | Chief Financial Officer |
| Christopher Vann | Chief Operating Officer |
| Olivia Manser | Head of Investor Relations |